Multiplexed Immunofluorescence

mIF

Multiplexed Immunofluorescence: a complete view of tumor behavior

Utilizing deep learning and advanced cell classification algorithms, multiplexed immunofluorescence spatial analysis uncovers the complex interplay between multitudes of immuno-oncology biomarkers and provides complete analysis of the tumor microenvironment. Multiplexed immunofluorescence has emerged as an effective and proficient approach to simultaneously identify specific proteins and immune cell types, to determine the spatial distribution and activation state of immune cells, as well as the expression of immune modulators, all at the same time. This method is highly beneficial for exploring immune evasion mechanisms and finding potential biomarkers that allow researchers to assess the mechanism of action and predict and monitor drug response.

NeoGenomics’ Pharma Services offer two multiplex immunofluorescence platforms: MultiOmyx and PhenoImager HT

MultiOmyx™

MultiOmyx is a proprietary, high-order multiplexing methodology that enables visualization and characterization of up to 60 proteins in a single FFPE tissue section.

High order ≥ 7 plex
Comprehensive analysis of tumor biology
Deep & precise immuno-profiling

Learn More

Akoya PhenoImager™

PhenoImager HT (formerly Vectra Polaris) is an automated system that allows simultaneous detection of 2-6 different markers from a single FFPE tissue slide which would provide a streamlined workflow for implementing refined low-order multiplex panel sets.

Low order 2-6 plex
High-throughput & faster TAT
Assay transfer & validation

Learn More

Latest Publications:

View All Publications

Optimization of an Integrated MultiOmyx-RNAscopehyperplexassay for co-detection and characterization of multiple protein and RNA biomarkers within the tumor microenvironment (TME)

SITC 2023
Presented
Nov 3, 2023
Type
Poster

Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyx immunofluorescence assay

AACR 2023
Presented
Apr 18, 2023
Type
Poster

Comprehensive analysis of natural killer cell-associated markers using MultiOmyx immunofluorescence assay

AACR 2023
Presented
Apr 18, 2023
Type
Poster

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients